Literature DB >> 21063289

Is pseudoexfoliation associated with sensorineural hearing loss?

Faruk Ozturk1, Emin Kurt, Umit U Inan, Sefa Derekoy, Sitki S Ermis, Ali Asagidag.   

Abstract

OBJECTIVE: To determine the possible relation between pseudoexfoliation (PSX) and sensorineural hearing loss.
METHODS: This study was carried out in Afyon Kocatepe University, Afyon, Turkey between July 2002 and June 2005. Sixty-three patients who were found to have ocular PSX on routine biomicroscopic examination, and 38 age-matched control subjects were evaluated for evidence of audiometric abnormality. The sum of pure-tone hearing threshold measured at 250-2000 Hz, 2000-6000 Hz, and 250-6000 Hz in each ear was compared with controls for the same frequencies.
RESULTS: The mean age of the patients was 68.4+/-10.3 years. All patients had PSX affecting at least one eye. Fifty (79.4%) patients with PSX, and 10 (26.3%) control subjects were found to have hearing loss (p=0.00, chi-square). From the 50 patients with PSX who had hearing loss, 34 patients had bilateral PSX, and 16 patients had unilateral PSX. Twenty-nine patients had high frequency hearing loss, while 20 patients had hearing loss in all frequencies. Forty-eight patients with PSX and 7 controls had bilateral sensorineural hearing loss (p=0.030).
CONCLUSION: Sensorineural hearing loss was seen more frequently in patients with PSX in comparison with age-matched control subjects.

Entities:  

Year:  2008        PMID: 21063289

Source DB:  PubMed          Journal:  Neurosciences (Riyadh)        ISSN: 1319-6138            Impact factor:   0.906


  2 in total

1.  Is there an association between pseudoexfoliation syndrome and knee osteoarthritis?

Authors:  M Ucar; U Sarp; K Kirboga; M Adam; H O Arik; F Gundogdu
Journal:  Z Rheumatol       Date:  2015-11       Impact factor: 1.372

2.  Association between Ocular Pseudoexfoliation and Sensorineural Hearing Loss.

Authors:  Nandini Vijaya Singham; Mimiwati Zahari; Mohammadreza Peyman; Narayanan Prepageran; Visvaraja Subrayan
Journal:  J Ophthalmol       Date:  2014-04-17       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.